ATE552851T1 - Zusammensetzungen zur behandlung von brust- und bauchspeicheldrüsenkrebs - Google Patents

Zusammensetzungen zur behandlung von brust- und bauchspeicheldrüsenkrebs

Info

Publication number
ATE552851T1
ATE552851T1 AT05722705T AT05722705T ATE552851T1 AT E552851 T1 ATE552851 T1 AT E552851T1 AT 05722705 T AT05722705 T AT 05722705T AT 05722705 T AT05722705 T AT 05722705T AT E552851 T1 ATE552851 T1 AT E552851T1
Authority
AT
Austria
Prior art keywords
compositions
breast
treatment
methods
pancreatic cancer
Prior art date
Application number
AT05722705T
Other languages
English (en)
Inventor
Michael Clarke
Muhammad Al-Hajj
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Priority claimed from PCT/US2005/003419 external-priority patent/WO2005074633A2/en
Application granted granted Critical
Publication of ATE552851T1 publication Critical patent/ATE552851T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05722705T 2004-02-03 2005-02-03 Zusammensetzungen zur behandlung von brust- und bauchspeicheldrüsenkrebs ATE552851T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54152704P 2004-02-03 2004-02-03
PCT/US2005/003419 WO2005074633A2 (en) 2004-02-03 2005-02-03 Compositions and methods for characterizing, regulating, diagnosing, and treating cancer

Publications (1)

Publication Number Publication Date
ATE552851T1 true ATE552851T1 (de) 2012-04-15

Family

ID=38019359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05722705T ATE552851T1 (de) 2004-02-03 2005-02-03 Zusammensetzungen zur behandlung von brust- und bauchspeicheldrüsenkrebs

Country Status (4)

Country Link
EP (1) EP2369014A1 (de)
CN (1) CN1950518A (de)
AT (1) ATE552851T1 (de)
ES (1) ES2383306T3 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201416832D0 (en) * 2014-09-24 2014-11-05 Glaxosmithkline Plc Methods of treatment
EP3284752B1 (de) * 2015-04-16 2020-07-01 Eisai R&D Management Co., Ltd. Anti-human-notch-4-antikörper

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6156305A (en) 1994-07-08 2000-12-05 Baxter International Inc. Implanted tumor cells for the prevention and treatment of cancer
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69718029T2 (de) 1996-10-11 2003-10-16 The Regents Of The University Of California, Oakland Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
WO2000020576A2 (en) * 1998-10-02 2000-04-13 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
US20030119029A1 (en) 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
WO2001053255A1 (en) 2000-01-24 2001-07-26 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
CN1780621A (zh) 2001-08-03 2006-05-31 先灵公司 作为γ分泌酶抑制剂的磺酰胺衍生物
CN1304390C (zh) 2001-08-03 2007-03-14 先灵公司 新颖的γ—分泌酶抑制剂
JP2005511754A (ja) * 2001-12-07 2005-04-28 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 乳癌幹細胞の予測的同定および特徴づけ

Also Published As

Publication number Publication date
ES2383306T3 (es) 2012-06-20
CN1950518A (zh) 2007-04-18
EP2369014A1 (de) 2011-09-28

Similar Documents

Publication Publication Date Title
WO2005074633A3 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
BR0315689A (pt) Alvo para terapia de dano cognitivo
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
MX350324B (es) Variantes derivadas de actriib y usos de las mismas.
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE602004020657D1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
MX2007009664A (es) Inhibidores de proteasoma y metodos para usar los mismos.
DE602007005353D1 (de) PyrazoloÄ1,5-aÜpyrimidine Derivate zur Verwendung in der Behandlung von Morbus Alzheimer und verwandten Leiden
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
DE602005026962D1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
DE602007010459D1 (de) Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
TW200716132A (en) Novel chemical compounds
ATE435224T1 (de) Neue piperidinsubstituierte diaminothiazole
FI20060246A0 (fi) Uusi kasvua stimuloiva proteiini ja sen käyttö